Arca
Skip to content
Tools
Tools

Dengue

Drug research and approvals for dengue: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 19, 2026, 24 studies of dengue are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, FDA has 0 approved and 7 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 24
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 24 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 3

Phase 2 5

Phase 1 or earlier 3

How its trials ended

242 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 79 whose ending is known, 70% met their primary endpoint, 9% missed it and 22% stopped early.

  • Completed, result not reported9840%
  • Met its primary endpoint5523%
  • Ongoing3916%
  • Status unknown2611%
  • Stopped: other or unclear125%
  • Missed its primary endpoint73%
  • Stopped: sponsor or business decision31%
  • Stopped: lack of efficacy1<1%
  • Stopped: enrollment or feasibility1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Mar 11, 2022A phase 2, randomized, double-blind, multicenter study to evaluate the safety and immunogenicity of three different potency levels of V181 (dengue quadrivalent…V181Merck & Co. (MSD)Ongoing

FDA orphan designations

Approved first, then open designations, newest first
Dec 18, 2023A phosphoramidate oral prodrug of a unique 6-modified…Treatment of disease caused by dengue virusAtea Pharmaceuticals Inc.Designated
Jun 21, 2023Recombinant human IgG1 neutralizing monoclonal antibody…Treatment of dengueAbViro LLCDesignated
Sep 1, 2021NafamostatTreatment of Dengue FeverRNR Biomedical incDesignated
Dec 26, 2017Arylalkyl 3-ketoindoleTreatment of dengue virus infectionJanssen Research & Development, LLCDesignated
May 18, 2016Liposomal glutathioneTreatment of Dengue Virus infection.Your Energy Systems, LLCDesignated
Aug 6, 2013Conjugate of a dengue virus specific small chemical ligand…Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)NanoViricides IncorporatedDesignated
Mar 3, 2003Polyinosinic-polycytidilic acidTreatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever,…OncovirDesignated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Dec 5, 2022QdengaDengue tetravalent vaccine (live, attenuated)Takeda Pharmaceuticals International AG Ireland BranchEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.